In a preclinical study, cytotoxic chemotherapy enhanced anticancer immunity through programmed cell death protein-1 inhibition, such as the release of potentially immunogenic tumor antigens induced by tumor cell death.18 The gene discussed is PDCD1; the disease is neoplasm.